2008 Financial Outlook
-- We expect our net revenue for 2008 will be approximately $75 to $82
-- We expect our gross margin for 2008 will be approximately 70% to 73%,
subject to quarterly fluctuations based on revenue mix.
-- Depending upon the progress of our clinical and pre-clinical programs,
we expect our research and development expenses in 2008 will be
approximately $34 to $38 million, including stock-based compensation
expense, which we estimate will be approximately $1.5 to $2 million.
-- We anticipate our selling, general, and administrative expenses for
2008 will be approximately $50 to $54 million, including stock-based
compensation expense, which we estimate will be approximately $2.5 to
ISTA will host a conference call with a simultaneous webcast today, March 6, 2008, at 5:00 PM Eastern Time, to discuss its fourth quarter and full-year 2007 results. To access the live conference call, U.S. and Canadian participants may dial 866-831-6270; international participants may dial 617-213-8858. The access code for the live call is 99457780. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the call is 57762235. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's
products and product candidates addressing the $4.7 billion U.S.
prescription ophthalmic industry include therapies for inflammation, ocular
pain, glaucoma, allergy, and dry eye. The Company currently markets three
products and is developing a strong
|SOURCE ISTA Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved